论文部分内容阅读
利用４５Ｃａ跨膜测量技术对中药复方——冠心舒治疗冠心病的研究结果表明，冠心舒不影响大鼠主动脉静流钙通道（ｌｅａｋ）的Ｃａ２＋内流，而对ＲＯＣ和ＰＤＣ的Ｃａ２＋内流有拮抗作用．当浓度为３０×１０－３ｇ／ｍＬ时，该药促使ＰＤＣ和ＲＯＣ的Ｃａ２＋内流量分别比对照下降２９×１０－６ｍｏｌ／ｋｇ和３６×１０－６ｍｏｌ／ｋｇ．这就说明，冠心舒治疗冠心病的药理，与阻滞钙通道和减少Ｃａ２＋内流有关．经拆方分析表明，全方的钙拮抗作用是补肾和活血功能药组协同作用的结果
The use of 45Ca transmembrane measurement technology on Chinese medicine compound - Guanxinshu treatment of coronary heart disease research results show that Guanxinshu does not affect Ca 2+ influx of rat aortic resting calcium channel (leak), but Ca 2+ for ROC and PDC Inflow has antagonism. When the concentration was 30×10-3g/mL, the drug promoted the internal flow of Ca2+ in PDC and ROC to be decreased by 29×10-6mol/kg and 36×10-6mol/kg, respectively. This shows that Guanxinshu treatment of coronary heart disease pharmacology, and block calcium channels and reduce Ca2+ influx. The analysis of the disassembled side showed that the calcium antagonism of the whole body is the result of the synergistic effect of the kidney and blood circulation functional drug group.